Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $7.31

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have earned an average recommendation of “Buy” from the four brokerages that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in the last year is $7.31.

A number of equities analysts have commented on AMRX shares. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, January 29th. Piper Sandler upped their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, March 4th. Finally, The Goldman Sachs Group upped their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the company a “buy” rating in a research note on Monday, March 4th.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of AMRX. Sanders Morris Harris LLC bought a new stake in shares of Amneal Pharmaceuticals during the 1st quarter valued at about $1,513,000. Vanguard Group Inc. grew its position in shares of Amneal Pharmaceuticals by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 13,642,387 shares of the company’s stock valued at $82,809,000 after buying an additional 94,087 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Amneal Pharmaceuticals by 2.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,118 shares of the company’s stock valued at $463,000 after buying an additional 1,949 shares during the last quarter. Legal & General Group Plc grew its position in shares of Amneal Pharmaceuticals by 738.9% during the 4th quarter. Legal & General Group Plc now owns 86,426 shares of the company’s stock valued at $525,000 after buying an additional 76,124 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Amneal Pharmaceuticals by 313.1% during the 4th quarter. Barclays PLC now owns 232,020 shares of the company’s stock valued at $1,408,000 after buying an additional 175,852 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $5.52 on Friday. Amneal Pharmaceuticals has a 12 month low of $1.33 and a 12 month high of $6.46. The company has a debt-to-equity ratio of 121.31, a current ratio of 1.63 and a quick ratio of 0.94. The firm has a market capitalization of $1.69 billion, a P/E ratio of -17.81 and a beta of 1.33. The company’s fifty day moving average price is $5.73 and its two-hundred day moving average price is $5.10.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Friday, March 1st. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. The firm had revenue of $616.98 million for the quarter, compared to analyst estimates of $630.67 million. On average, research analysts anticipate that Amneal Pharmaceuticals will post 0.5 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.